Sen Parikshit, Dabas Aashima, Kumar Ravindra, Yadav Sangeeta
Department of Pediatrics, Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, India.
Department of Pediatrics, Hindu Rao Hospital, New Delhi, India.
J Obstet Gynaecol India. 2025 Apr;75(Suppl 1):129-134. doi: 10.1007/s13224-024-02031-2. Epub 2024 Jul 3.
Variable anthropometric and pubertal outcomes are reported in children with central precocious puberty (CPP) based on treatment choices and practices. We aimed to measure growth and pubertal progression in these children and associate with quality of life in relation to therapy received.
This observational study enrolled children with CPP who were receiving/had received gonadotropin releasing hormone analog (GnRHa). The baseline and follow-up clinical details were recorded. Quality of life was assessed using PedsQL 4.0 at the last follow up visit.
Twenty-three children (21girls, 2 boys) with CPP, having a median (IQR) age of 6.75 (5.23, 8.25) years were enrolled. The mean (SD) height SDS was 0.45 (1.20) and BMI-SDS 0.65 (1.06). The median (IQR) follow-up duration was 4.4 (2.5-5.1) years. Twelve children completed their treatment and progressed through puberty normally.Mean bone age/chronological age (BA/CA) ratio decreased from baseline 1.46 to 1.23 at follow-up, < 0.001. A significant negative correlation was seen between age of start of GnRH therapy and growth velocity on follow-up ( = - 0.598; = 0.003). The mean (SD) PedsQL scores for total, psychosocial and physical health were 59.02 (22.76), 58.41 (22.83), and 60.73 (25.56), respectively, with lower scores in shorter, older and post-menarcheal girls ( > 0.05).
Our study found favorable anthropometric outcomes with resumption of normal puberty after completion of GnRH therapy. The quality of life outcomes were favorable with early and adequate GnRH therapy.
根据治疗选择和实践，中枢性性早熟（CPP）儿童报告了不同的人体测量和青春期结局。我们旨在测量这些儿童的生长和青春期进展，并将其与所接受治疗的生活质量相关联。
这项观察性研究纳入了正在接受/已接受促性腺激素释放激素类似物（GnRHa）治疗的CPP儿童。记录基线和随访的临床细节。在最后一次随访时使用儿童生活质量量表4.0（PedsQL 4.0）评估生活质量。
纳入了23例CPP儿童（21例女孩，2例男孩），中位（四分位间距）年龄为6.75（5.23，8.25）岁。平均（标准差）身高标准差分数（SDS）为0.45（1.20），体重指数标准差分数（BMI-SDS）为0.65（1.06）。中位（四分位间距）随访时间为4.4（2.5 - 5.1）年。12名儿童完成治疗并正常度过青春期。平均骨龄/实际年龄（BA/CA）比值从基线时的1.46降至随访时的1.23，P < 0.001。GnRH治疗开始年龄与随访时的生长速度之间存在显著负相关（r = - 0.598；P = 0.
